Cullinan Therapeutics (NASDAQ: CGEM) resets CLN-978 data to 1H 2026

Rhea-AI Filing Summary

Cullinan Therapeutics, Inc. reported that it has refreshed its corporate presentation, which it uses in meetings with third parties and posts on its website, and has furnished the updated materials as an exhibit. The company also revised the anticipated timing for announcing initial clinical data from its CLN-978 program in systemic lupus erythematosus, now expecting this readout in the first half of 2026. The expected timelines for clinical data announcements from all of its other programs remain the same.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001789972false00017899722025-09-042025-09-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 04, 2025

CULLINAN THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39856	81-3879991
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
One Main Street Suite 1350
Cambridge, Massachusetts				02142
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 617 410-4650

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		CGEM		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Cullinan Therapeutics, Inc. (the "Company") updated its corporate presentation, used from time to time in meetings with third parties and posted to its website. A copy of the current presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

The Company updated its anticipated timeline of announcing initial clinical data for its CLN-978 program in systemic lupus erythematosus to be in the first half of 2026. The anticipated timeline for the announcement of clinical data for all of the Company's other programs remains unchanged.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Corporate Presentation
104		Cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			CULLINAN THERAPEUTICS, INC.
Date:	September 4, 2025	By:	/s/ Mary Kay Fenton
			Mary Kay Fenton Chief Financial Officer

FAQ

What did Cullinan Therapeutics (CGEM) disclose in this 8-K?

Cullinan Therapeutics disclosed that it updated its corporate presentation, which is used with third parties and posted on its website, and furnished the new version as an exhibit.

How did Cullinan Therapeutics (CGEM) change the CLN-978 clinical data timeline?

Cullinan Therapeutics updated its anticipated timeline for announcing initial clinical data for its CLN-978 program in systemic lupus erythematosus to be in the first half of 2026.

Did Cullinan Therapeutics change timelines for its other programs?

No. The company stated that the anticipated timelines for the announcement of clinical data for all of its other programs remain unchanged.

Is the updated Cullinan Therapeutics corporate presentation considered filed with the SEC?

No. The company stated that the information in the Regulation FD disclosure item, including the corporate presentation exhibit, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act.

What exhibit did Cullinan Therapeutics (CGEM) include with this 8-K?

Cullinan Therapeutics included Exhibit 99.1, described as a corporate presentation, and identified the cover page formatted in Inline XBRL as Exhibit 104.

Who signed this Cullinan Therapeutics (CGEM) report?

The report was signed on behalf of Cullinan Therapeutics, Inc. by Mary Kay Fenton, Chief Financial Officer.